TGFβR antagonists

1. The compound of the formula

wherein:

R is

or a heterocyclic or heterobicyclic group substituted with 0-4 R 2 ;

X 1 , X 2 , X 3 and X 4 are independently —CH— or —N—, wherein at least one is —N—;

R 1 is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 , any of which except the hydrogen is substituted with 0-3 R x ;

R x is hydrogen, halogen, —OH, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, or —CN;

R 2 is independently one or more hydrogen, —CD 3 , OCD 3 , halogen, —CF 3 , —CHF 2 , —CN, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy or —SO 2 (C 1 -C 6 )alkyl;

R 3 is independently one or more hydrogen, CD 3 , OCD 3 , halogen, —CN, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, hydroxy(C 1 -C 3 )alkyl, (C 1 -C 6 )alkylamino-, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, —NR 5 R 6 , —CONR 5 R 6 , —COOR 4 , —COR 4 , —SO 2 R 4 , —CHCF 2 COOCH 2 OH or —CHCF 2 CONH 2 , any of which except the hydrogen is substituted with 0-4 R y ;

R y is hydrogen, halogen, —OH, (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, —NHCOOH, or —CN;

R 4 is hydrogen or (C 1 -C 6 )alkyl;

R 5 and R 6 are independently hydrogen, —C(O)alkyl or (C 1 -C 6 )alkyl; or

R 5 and R 6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;

R 7 is independently one or more hydrogen, halogen, halo(C 1 -C 6 )alkyl or —CN;

R 8 is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 ;

R 9 is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, heterocyclylalkyl-, heterocyclyl(C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl- or (C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2 or 3;

and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

2. A compound according to claim 1 of formula (II)

wherein:

X 1 , X 2 , X 3 and X 4 are independently —CH— or —N—, wherein at least one is —N—;

R 1 is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 , any of which except the hydrogen is substituted with 0-3 R x ;

R x is hydrogen, halogen, —OH, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, or —CN;

R 2 is independently one or more hydrogen, —CD 3 , OCD 3 , halogen, —CF 3 , —CHF 2 , —CN, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy or —SO 2 (C 1 -C 6 )alkyl;

R 3 is independently one or more hydrogen, CD 3 , OCD 3 , halogen, —CN, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, hydroxy(C 1 -C 3 )alkyl, (C 1 -C 6 )alkylamino-, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, —NR 5 R 6 , —CONR 5 R 6 , —COOR 4 , —COR 4 , —SO 2 R 4 , —CHCF 2 COOCH 2 OH or —CHCF 2 CONH 2 , any of which except the hydrogen is substituted with 0-4 R y ;

R y is hydrogen, halogen, —OH, (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, —NHCOOH, or —CN;

R 4 is hydrogen or (C 1 -C 6 )alkyl;

R 5 and R 6 are independently hydrogen, —C(O)alkyl or (C 1 -C 6 )alkyl; or

R 5 and R 6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;

R 7 is independently one or more hydrogen, halogen, halo(C 1 -C 6 )alkyl or —CN;

R 8 is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 ;

R 9 is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, heterocyclylalkyl-, heterocyclyl(C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl- or (C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2 or 3;

and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

3. A compound according to claim 2 of the formula

wherein:

X 1 , X 2 , X 3 and X 4 are independently —CH— or —N—, wherein at least one is —N—;

R 1 is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 , any of which except the hydrogen is substituted with 0-3 R x ;

R x is hydrogen, halogen, —OH, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, or —CN;

R 2 is independently one or more hydrogen, —CD 3 , OCD 3 , halogen, —CF 3 , —CHF 2 , —CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or —SO 2 (C 1 -C 3 )alkyl;

R 3 is independently one or more hydrogen, CD 3 , OCD 3 , halogen, —CN, (C 1 -C 3 )alkyl, (C 2 -C 6 )alkenyl, (C 1 -C 3 )alkoxy, (C 3 -C 8 )cycloalkyl, hydroxy(C 1 -C 3 )alkyl, (C 1 -C 3 )alkylamino-, (C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, —NR 5 R 6 , —CONR 5 R 6 , —COOR 4 , —COR 4 , —SO 2 R 4 , —CHCF 2 COOCH 2 OH or —CHCF 2 CONH 2 , any Of which except the hydrogen is substituted with 0-4 R y ;

R y is hydrogen, halogen, —OH, (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, —NHCOOH, or —CN;

R 4 is hydrogen or (C 1 -C 6 )alkyl;

R 5 and R 6 are independently hydrogen, —C(O)alkyl or (C 1 -C 6 )alkyl; or

R 5 and R 6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;

R 7 is independently one or more hydrogen, halogen, halo(C 1 -C 6 )alkyl or —CN;

R 8 is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 5 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 ;

R 9 is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, heterocyclylalkyl-, heterocyclyl(C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl- or (C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2 or 3;

and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

4. A compound according to claim 3 of the formula

wherein:

X 1 and X 2 are independently —CH or —N—, wherein at least one is —N—;

R 1 is hydrogen, (C 1 -C 3 )alkyl, (C 3 -C 8 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 , any of which except the hydrogen is substituted with 0-3 R x ;

R x is hydrogen, halogen, —OH, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, or —CN;

R 2 is independently one or more hydrogen, —CD 3 , OCD 3 , halogen, —CF 3 , —CHF 2 , —CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or —SO 2 (C 1 -C 3 )alkyl;

R 3 is independently one or more hydrogen, CD 3 , OCD 3 , halogen, —CN, (C 1 -C 3 )alkyl, (C 2 -C 6 )alkenyl, (C 1 -C 3 )alkoxy, (C 3 -C 8 )cycloalkyl, hydroxy(C 1 -C 3 )alkyl, (C 1 -C 3 )alkylamino-, (C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, —NR 5 R 6 , —CONR 5 R 6 , —COOR 4 , —COR 4 , —SO 2 R 4 , —CHCF 2 COOCH 2 OH or —CHCF 2 CONH 2 , any of which except the hydrogen is substituted with 0-4 R y ;

R y is hydrogen, halogen, —OH, (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, —NHCOOH, or —CN;

R 4 is hydrogen or (C 1 -C 3 )alkyl;

R 5 and R 6 are independently hydrogen, —C(O)alkyl or (C 1 -C 3 )alkyl; or

R 5 and R 6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;

R 7 is independently one or more hydrogen, halogen, halo(C 1 -C 3 )alkyl or —CN;

R 8 is hydrogen, (C 1 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 ;

R 9 is hydrogen, (C 1 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl, heterocyclylalkyl-, heterocyclyl(C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl- or (C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl;

m is 0, 1, 2, 3, or 4;

and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

5. A compound according to claim 4 of the formula

wherein:

X 1 and X 2 are independently —CH or —N—, wherein at least one is —N—;

R 1 is hydrogen, (C 1 -C 3 )alkyl, (C 4 -C 6 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 , any of which except the hydrogen is substituted with 0-3 R x ;

R x is hydrogen, halogen, —OH, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, or —CN;

R 2 is independently one or more hydrogen, —CD 3 , OCD 3 , halogen, —CF 3 , —CHF 2 , —CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or —SO 2 (C 1 -C 3 )alkyl;

R 3 is independently one or more hydrogen, CD 3 , OCD 3 , halogen, —CN, (C 1 -C 3 )alkyl, (C 2 -C 6 )alkenyl, (C 1 -C 3 )alkoxy, (C 3 -C 8 )cycloalkyl, hydroxy(C 1 -C 3 )alkyl, (C 1 -C 3 )alkylamino-, (C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, —NR 5 R 6 , —CONR 5 R 6 , —COOR 4 , —COR 4 , —SO 2 R 4 , —CHCF 2 COOCH 2 OH or —CHCF 2 CONH 2 , any of which except the hydrogen is substituted with 0-4 R y ;

R y is hydrogen, halogen, —OH, (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, —NHCOOH, or —CN;

R 4 is hydrogen or methyl;

R 5 and R 6 are independently hydrogen, —C(O)alkyl or (C 1 -C 3 )alkyl; or

R 5 and R 6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;

R 7 is independently one or more hydrogen, halogen, halo(C 1 -C 3 )alkyl or —CN;

R 8 is hydrogen, (C 1 -C 3 )alkyl, or —COR 9 ;

R 9 is hydrogen, (C 1 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl, heterocyclylalkyl-, heterocyclyl(C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl- or (C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl;

m is 0, 1 or 2;

and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

6. A compound according to claim 1 wherein:

R is thiazole, thiadiazole, thiophene, pyrazole, isoquinoline, indole or quinoline substituted with 0-4 R 2 ;

R 1 is hydrogen, (C 1 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 , any of which except the hydrogen is substituted with 0-3 R x ;

R x is hydrogen, halogen, —OH, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, or —CN;

R 2 is independently one or more hydrogen, —CD 3 , OCD 3 , halogen, —CF 3 , —CHF 2 , —CN, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy or —SO 2 (C 1 -C 6 )alkyl;

R 3 is independently one or more hydrogen, CD 3 , OCD 3 , halogen, —CN, (C 1 -C 3 )alkyl, (C 2 -C 6 )alkenyl, (C 1 -C 3 )alkoxy, (C 3 -C 8 )cycloalkyl, hydroxy(C 1 -C 3 )alkyl, (C 1 -C 3 )alkylamino-, (C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, —NR 5 R 6 , —CONR 5 R 6 , —COOR 4 , —COR 4 , —SO 2 R 4 , —CHCF 2 COOCH 2 OH or —CHCF 2 CONH 2 , any of which except the hydrogen is substituted with 0-4 R y ;

R y is hydrogen, halogen, —OH, (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, —NHCOOH, or —CN;

R 4 is hydrogen or methyl;

R 5 and R 6 are independently hydrogen, —C(O)alkyl or (C 1 -C 3 )alkyl;

R 7 is independently one or more hydrogen, halogen, halo(C 1 -C 3 )alkyl or —CN;

R 8 is hydrogen, (C 1 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl, —CONHR 9 , —COOR 9 , —COR 9 or —SO 2 R 9 ;

R 9 is hydrogen, (C 1 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl, heterocyclylalkyl-, heterocyclyl(C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl- or (C 1 -C 3 )alkylamino(C 1 -C 3 )alkyl;

n is 0, 1, 2 or 3;

and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

7. A compound according to claim 6 wherein:

R is thiazole, pyrazole, isoquinoline, indole or quinoline substituted with 0-4 R 2 ;

R 1 is —COR 9 substituted with 0-2 R x ;

R x is hydrogen, halogen, —OH, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, or —CN;

R 2 is independently one or more hydrogen, —CD 3 , OCD 3 , halogen, —CF 3 , —CHF 2 , —CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or —SO 2 (C 1 -C 3 )alkyl;

R 3 is independently one or more hydrogen, halogen, —CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, (C 3 -C 6 )cycloalkyl, 5-6 membered heteroaryl, heterocyclo, —NR 5 R 6 , —CONR 5 R 6 , —COOR 4 , —SO 2 R 4 or (C 1 -C 3 )alkylamino substituted with 0-2 R y ;

R y is hydrogen, halogen, —OH, (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, -amino(C 1 -C 3 )alkyl, —NHCOOH, or —CN;

R 4 is hydrogen or methyl;

R 5 and R 6 are independently hydrogen, —C(O)alkyl or (C 1 -C 3 )alkyl;

R 7 is independently one or more hydrogen, halogen, halo(C 1 -C 3 )alkyl or —CN;

R 8 is hydrogen;

R 9 is hydrogen, (C 1 -C 3 )alkyl or (C 3 -C 6 )cycloalkyl;

n is 0, 1 or 2;

and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

8. A compound according to claim 7 wherein:

R is thiazole, isoquinoline, indole or quinoline substituted with 0-4 R 2 ;

R 1 is —COR 9 ;

R 2 is independently one or more hydrogen, halogen, —CF 3 , —CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or —SO 2 (C 1 -C 3 )alkyl;

R 3 is independently one or more hydrogen, halogen, —CN or (C 1 -C 3 )alkyl;

R 7 is independently one or more hydrogen, halogen, halo(C 1 -C 3 )alkyl or —CN;

R 8 is hydrogen;

R 9 is hydrogen or (C 1 -C 3 )alkyl;

n is 0, 1 or 2;

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

9. A compound according to claim 1 selected from the following

N-{4-[6-Fluoro-3-(6-methoxypyridin-3-yl)-H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide,

N-{4-[6-Chloro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-{[3-(morpholin-4-yl)propyl]amino}acetamide,

N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-(methoxy-d3)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide,

N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-ethoxy-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide,

N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-ethoxy-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,

N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(dimethylamino)methyl]-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,

N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(hydroxymethyl)-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,

N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(1-hydroxyethyl)-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,

N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(1R)-1-hydroxyethyl]-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,

N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(1 S)-1-hydroxyethyl]-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,

N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(methylamino)methyl]-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,

N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(2-hydroxypropan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,

N-(4-(7-(1-Hydroxyethyl)-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide,

N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide, or

N-(4-(6-Methoxy-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide;

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

10. A compound according to claim 1 selected from the following

N-{4-[3-(6-Methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide,

N-{4-[6-Chloro-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide,

N-(4-(3-(5-(Methoxy-d 3 )pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide,

N-(4-(6-Chloro-3-(5-(methoxy-d3)pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide,

N-(4-(6-Fluoro-3-(5-(methoxy-d3)pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide,

N-(4-(6-Methoxy-3-(5-(methoxy-d3)pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide,

N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide, or

N-(4-(6-Methoxy-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

11. A pharmaceutical composition which comprises a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.

12. A combination pharmaceutical product comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with one or more other therapeutically active agents.

13. A method of treating cancer in a subject in need thereof which comprises administering a therapeutically effective amount of compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the cancer is small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, ovarian cancer, colorectal cancer, prostate cancer, melanoma, pancreatic cancer, multiple myeloma, T-acute lymphoblastic leukemia or AML.